Amolyt Pharma
Main Menu

News & Media

Main Menu

Press Releases

Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

January 24, 2023
Download a PDF: EN or FR

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

January 6, 2023
Download a PDF: EN or FR

Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

October 12, 2022
Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)

KOL Webinar on AZP-3601 Featuring Professor István Takács

Written by
jpoly4
Eneboparatide (AZP-3601)

Development of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ). ASBMR Poster.

Written by
Dan Hennings
Eneboparatide (AZP-3601)

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

Written by
Dan Hennings
AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

Written by
jpoly4
AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

Written by
jpoly4

Upcoming events

Date: May 13-16, 2023 (Istanbul, Turkey)

Date: June 15-18, 2023 (Chicago, IL)

Date: October 13-16, 2023 (Vancouver, Canada)

Social Updates

TWITTER

Scroll to Top